Research Topics
Species | M A PetriSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation studyMichelle Petri
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
Arthritis Rheum 65:1011-21. 2013..To evaluate the safety and tolerability of multiple intravenous (IV) doses of sifalimumab in adults with moderate-to-severe systemic lupus erythematosus (SLE)...
Unmet medical needs in systemic lupus erythematosusAisha Lateef
Division of Rheumatology, Johns Hopkins University, School of Medicine, Johns Hopkins Lupus Center, 1830 E, Monument Street, Suite 7500, Baltimore, MD 21205, USA
Arthritis Res Ther 14:S4. 2012..The current review will highlight some of the outstanding unmet challenges in the management of this complex disease...- Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus CohortMichelle Petri
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Arthritis Rheum 64:4021-8. 2012..We analyzed data from a large SLE cohort to identify variables associated with rates of damage accrual as measured by the SDI... - Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusMichelle Petri
Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
Arthritis Rheum 64:2677-86. 2012.... - Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosisLindsey E Romick-Rosendale
Department of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA
Arthritis Res Ther 13:R199. 2011.... - Seasonal variation in the activity of systemic lupus erythematosusAlí Duarte-García
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
J Rheumatol 39:1392-8. 2012..To determine whether there is any seasonal variation in the activity of systemic lupus erythematosus (SLE) overall and by individual organs... - Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritisAdnan N Kiani
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
J Rheumatol 39:1231-7. 2012..Both VCAM-1 and NGAL have been found at high levels in the urine of patients with active lupus nephritis. We investigated both as potential biomarkers for lupus nephritis... - Differences between male and female systemic lupus erythematosus in a multiethnic populationTze Chin Tan
Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
J Rheumatol 39:759-69. 2012..Comparisons were made between male and female patients with SLE in the Hopkins Lupus Cohort... - Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosusJanet W Maynard
Johns Hopkins University School of Medicine, 1830 East Monument St, Suite 7500, Baltimore, MD 21205, USA
J Rheumatol 39:777-83. 2012..We investigated whether education or income levels are associated with cardiovascular risk factors and outcomes in SLE... - High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trialMichelle Petri
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
Arthritis Rheum 62:1487-93. 2010..We undertook this study to compare the efficacy and safety of the standard regimen versus a high-dose IV cyclophosphamide regimen... - Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective studyMichelle Petri
Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Suite 7500, Baltimore, Maryland 21205, USA
J Rheumatol 36:2476-80. 2009..We determined the prevalence of and risk factors for British Isles Lupus Activity Group (BILAG) flare in patients with systemic lupus erythematosus (SLE)... - Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosusM Petri
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Lupus 18:980-9. 2009..In summary, although higher IFNr scores were associated with greater disease activity, IFNr scores of individual patients did not correlate with changes in disease severity or flare risk... 
Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosusMichelle Petri
Johns Hopkins University, Baltimore, Maryland 21205, USA
J Rheumatol 35:2348-54. 2008..We wished to determine the prevalence of cerebral atrophy and focal lesions in a cohort of patients with newly diagnosed systemic lupus erythematosus (SLE) and the association of these brain abnormalities with clinical characteristics...- Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trialMichelle Petri
Johns Hopkins University, Baltimore, MD 21205, USA
Semin Arthritis Rheum 41:194-202. 2011..We investigated whether it had benefit for SLE cognitive impairment... - Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus CohortM Petri
Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland 21205, USA
Lupus 19:419-23. 2010..Anti-phospholipid antibodies are not associated with atherosclerosis... - Depression and cognitive impairment in newly diagnosed systemic lupus erythematosusMichelle Petri
Johns Hopkins University, Suite 7500, Baltimore, Maryland 21205, USA
J Rheumatol 37:2032-8. 2010..The natural history of cognitive dysfunction in newly diagnosed SLE is unknown. We examined the association of depression and cognitive performance in newly diagnosed SLE... - Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosusTaraneh Mehrani
Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
J Rheumatol 38:64-8. 2011..Multiple studies have found a high prevalence of IgA anti-ß(2)-GPI in systemic lupus erythematosus (SLE). We determined the frequency and associations of IgA anti-ß(2)-GPI in a cohort of patients with SLE... - Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patientsMichelle Petri
Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
Curr Rheumatol Rep 13:77-80. 2011..This article reviews its possible role as an antithrombotic drug in the general population, in systemic lupus erythematosus, and in patients with antiphospholipid antibodies... - Lupus Atherosclerosis Prevention Study (LAPS)M A Petri
Professor of Medicine, Johns Hopkins University, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA
Ann Rheum Dis 70:760-5. 2011..A study was undertaken to investigate whether treatment with statins would reduce subclinical measures of atherosclerosis over a 2-year period... - Clinical research in systemic lupus erythematosus: immediate relevance to clinical practiceMichelle Petri
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
Int J Rheum Dis 14:1-5. 2011..Greater appreciation of cognitive impairment and of lupus myelitis is now possible. Pregnancy risks are better characterized. However, the greatest unmet challenge remains atherosclerosis... - Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusMichelle Petri
Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD 21205, USA
Arthritis Rheum 58:2453-9. 2008..To determine the association of plasma B lymphocyte stimulator (BLyS) levels, immunosuppressive therapy, and other clinical parameters with disease activity in systemic lupus erythematosus (SLE)... - Cognitive function in a systemic lupus erythematosus inception cohortMichelle Petri
Johns Hopkins University, Baltimore, MD, USA
J Rheumatol 35:1776-81. 2008..Measurable cognitive impairment occurs in 30-75% of patients with systemic lupus erythematosus (SLE). We compared cognitive functioning in recently-diagnosed SLE patients and normal controls... - Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response indexMichelle Petri
Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21205, USA
Arthritis Rheum 58:1784-8. 2008..To develop a measure of renal activity in systemic lupus erythematosus and use it to develop a renal response index... - Cyclophosphamide: new approaches for systemic lupus erythematosusM Petri
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Lupus 13:366-71. 2004..This review will touch on the traditional intravenous 'pulse' cyclophosphamide regimen, consider its toxicity, and contrast it with newer approaches to cyclophosphamide... - Prospective study of systemic lupus erythematosus pregnanciesM Petri
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Lupus 13:688-9. 2004..Pregnancy loss occurred in 14%. Active SLE contributes to both preterm birth and to pregnancy loss. In addition, even in a first pregnancy, the presence of the lupus anticoagulant is associated with an increased risk of pregnancy loss... - Classification criteria for systemic lupus erythematosus: a reviewM Petri
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Lupus 13:829-37. 2004..These critical reviews, discussed at the Lund, Sweden, meeting in 2003, will be useful to the clinician and to the researcher. This paper reviews and critiques previous classification attempts... - Review of classification criteria for systemic lupus erythematosusMichelle Petri
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Rheum Dis Clin North Am 31:245-54, vi. 2005..Other classification criteria, emphasizing weighting or recursive partitioning, exist, but they are more cumbersome. Revised criteria are needed, not just for systemic lupus erythematosus, but also for chronic cutaneous lupus... - Systemic lupus erythematosus: 2006 updateMichelle Petri
Department of Medicine, Lupus Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
J Clin Rheumatol 12:37-40. 2006 - Management of antiphospholipid syndrome in pregnancyMichelle Petri
Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, 1830 E Monument 7500, East Baltimore Campus, Baltimore, MD 21205, USA
Rheum Dis Clin North Am 32:591-607. 2006..New research on the role of complement activation in murine APS pregnancy loss may change therapeutic options in the future... - Disease activity assessment in SLE: do we have the right instruments?Michelle Petri
Johns Hopkins University School of Medicine, Division of Rheumatology, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA
Ann Rheum Dis 66:iii61-4. 2007..This has led, understandably, to concern that there is something wrong with SLE trial designs, particularly with SLE disease activity indices... - Monitoring systemic lupus erythematosus in standard clinical careMichelle Petri
Johns Hopkins University School of Medicine, 1830 E Monument St Suite 7500, Baltimore, MD 21205, USA
Best Pract Res Clin Rheumatol 21:687-97. 2007..Disease activity indices and a cumulative history summary can be used to track complicated patients over time. Monitoring guidelines for damage from the disease and for the toxicity of treatment are available... - Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal responseMichelle Petri
Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21205, USA
Arthritis Rheum 58:1789-95. 2008..To assess the degree to which physicians agree with each other and with ratings obtained with 3 existing responder indices, in rating the response to treatment of lupus nephritis... - The Hopkins Lupus Pregnancy Center: ten key issues in managementMichelle Petri
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Rheum Dis Clin North Am 33:227-35, v. 2007..These key issues will be examined in this chapter... - Soluble CD154 is not associated with atherosclerosis in systemic lupus erythematosusAdnan Kiani
Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland 20852, USA
J Rheumatol 34:969-72. 2007..We determined the association of sCD154 with coronary calcium and carotid plaque at the baseline visit of the Lupus Atherosclerosis Prevention Study... - Sex hormones and systemic lupus erythematosusM Petri
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21093, USA
Lupus 17:412-5. 2008..The role of estrogen, prolactin, pregnancy and androgen (including DHEA) in SLE is reviewed. A comlex interaction of multiple sex hormones is involved in SLE... - Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosusAdnan N Kiani
Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine Baltimore, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA
Rheumatology (Oxford) 50:2071-9. 2011..Cardiovascular disease remains the major cause of death in SLE. We assessed the degree to which cardiovascular risk factors (CVRFs) and disease activity were associated with 2-year changes in measures of subclinical atherosclerosis... - IgM anti-β2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosusTaraneh Mehrani
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
J Rheumatol 38:450-3. 2011..We investigated whether IgM anti-ß(2)-glycoprotein I (anti-ß(2)-GPI) is associated with clinical manifestations of systemic lupus erythematosus (SLE)... - Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics groupSean J Wollaston
Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
J Rheumatol 31:2390-4. 2004..CONCLUSION: The physician VAS may be too blunt to assess response in SLE, because even among experienced lupus assessors, there were considerable differences in what influenced scoring decisions... - Neuropsychiatric systemic lupus erythematosus: miles to go before we sleepRobin L Brey
Neurology 61:9-10. 2003 - Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosusMichelle A Petri
Johns Hopkins University Medical Center, Baltimore, Maryland 21205, USA
Arthritis Rheum 50:2858-68. 2004..To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms... - Classification criteria for antiphospholipid syndrome: the case for cardiac valvular diseaseMichelle A Petri
J Rheumatol 31:2329-30. 2004 - The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosusKathleen E Sullivan
Allergy Immunology, The Children s Hospital of Philadelphia, 34th Street and Civic Ctr Boulevard, Philadelphia, PA 19104, USA
Clin Immunol 123:74-81. 2007..Histone acetylation, associated with increased transcriptional competence of TNFalpha, may play a role in certain inflammatory aspects of the disease... - The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trialJill P Buyon
Hospital for Joint Diseases, New York University School of Medicine, New York, New York, USA
Ann Intern Med 142:953-62. 2005..There is concern that exogenous female hormones may worsen disease activity in women with systemic lupus erythematosus (SLE)... - Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flaresIrene M Vasiliu
Department of Medicine, State University of New York at Buffalo, New York, USA
J Rheumatol 33:1878-80. 2006..Our experience suggests that G-CSF therapy should be used with considerable caution in patients with SLE... - Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trialMichelle A Petri
Department of Medicine, John Hopkins Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
Arthritis Rheum 46:1820-9. 2002..5 mg/day for 2 months or longer while maintaining stable or reduced disease activity in steroid-dependent women with systemic lupus erythematosus (SLE)...
Research Grants
- Brain ConnectionsMichelle Petri; Fiscal Year: 2006..abstract_text> ..
- Revision of ACR Classification Criteria for Systemic Lupus ErythematosusMichelle Petri; Fiscal Year: 2007..This project will lead to updated, validated SLE classification criteria that can be immediately used by both industry and academic clinical trials. ..
- Lupus CohortMichelle Petri; Fiscal Year: 2006..Fourth, we will assess, in 100 SLE patients with and 100 without fibromyalgia, the frequency of autonomic neuropathy and the correlation with health status. ..
- HOPKINS LUPUS COHORTMichelle Petri; Fiscal Year: 2001..Understanding the basis of change in health status measures is necessary to justify the future use of these measures as efficacy outcomes in clinical trials. ..
- HOPKINS LUPUS COHORTMichelle A Petri; Fiscal Year: 2010..This project addresses three challenges: hardening of the arteries, blood clots, and lupus kidney disease in collaboration with other rheumatologists and radiologists. ..